Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Innovent/IASO Release Strong Long-Term Data on CAR-T for Multiple Myeloma

publication date: Jun 8, 2023

Suzhou Innovent and Nanjing’s IASO Bio presented positive long-term follow-up results of a Phase Ib/II trial of their partnered BCMA CAR T-cell therapy in relapsed and/or refractory multiple myeloma patients. The data, which was released at the ASCO meeting, showed equecabtagene autoleucel achieved an overall response rate of 96%. 91% of the patients showed at least a very good partial response, and 74% had either a stringent complete response or a complete response. The enrolled patients, who had previously been treated with at least three rounds of treatment, were refractory to their previous therapy round. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital